Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Innovative combination strategy to enhance effect and diminish adverse effects of glucocorticoids: another promise? | Available online http content 11 1 105 Editorial Innovative combination strategy to enhance effect and diminish adverse effects of glucocorticoids another promise Johannes WG Jacobs and Johannes WJ Bijlsma Department of Rheumatology Clinical Immunology University Medical Center Utrecht . Box 85500 3508 GA Utrecht The Netherlands Corresponding author Johannes WG Jacobs Published 27 February 2009 Arthritis Research Therapy 2009 11 105 doi ar2615 This article is online at http content 11 1 105 2009 BioMed Central Ltd See related research by Zimmermann et al. http content 11 1 R12 Abstract In a paper by Zimmermann and colleagues in this issue of Arthritis Research Therapy results of extended laboratory research with the drug combination of prednisolone and dipyridamole are reported. There seems to be a boost and extension of the glucocorticoid effect by the combination without a clear increase of adverse effects potentially allowing the application of lower dosages. However laboratory models are not patients and the glucocorticoid mechanisms leading to effects and adverse effects are manifold. The next required step will be to demonstrate the improved therapeutic window in patients in adequate comparative clinical trials assessing predefined beneficial effects and adverse effects in a standardized way. In this issue of Arthritis Research Therapy Zimmermann and colleagues employees of CombinatoRx 1 a company that specializes in finding and developing synergistic combinations of existing drugs report on extended in vivo rats and mice and in vitro research with the combination of the drugs prednisolone and dipyridamole 2 . The results suggest that this combination has a synergistic immunosuppressive effect. Dipyridamole is a phosphodiesterase inhibitor that increases intracellular levels of cyclic adenosine and guanine monophosphate by inhibiting their .
